Group 1 - The company, Nanjing Novogene Bioinformatics Technology Co., Ltd., reported on the status of its fundraising and usage of funds for the first half of 2025, confirming compliance with relevant regulations [1][2][3] - The total amount raised through the public offering was RMB 2,200,550,000, with a net amount of RMB 2,109,170,220 after deducting issuance costs [1][2] - As of June 30, 2025, the company had used RMB 215,504.71 million of the raised funds, with RMB 5,022.05 million used during the reporting period [4][5] Group 2 - The company established a dedicated fund management system, ensuring that the raised funds are stored in a special account and used according to regulations [3][4] - No idle funds were temporarily used to supplement working capital during the reporting period, and no funds were used for cash management or investment in related products [5][6] - The company approved the completion of certain fundraising projects and decided to permanently supplement working capital with the remaining funds [6][7] Group 3 - The company signed a cooperation development agreement with Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. to collaborate on Alzheimer's Disease (AD) screening and cell therapy projects [18][19] - A joint venture named Beijing Weimiao Biotechnology Co., Ltd. will be established, with both companies holding a 50% stake and an initial registered capital of RMB 40 million [18][19] - The joint venture aims to leverage both companies' strengths in AD screening and cell therapy to enhance their competitive edge in the market [38][39] Group 4 - The company plans to invest in the joint venture through its own funds, with the first phase focusing on developing production processes and conducting clinical trials for cell therapies [25][26] - The governance structure of the joint venture includes a board of directors and a project joint development committee to oversee operations and ensure compliance with the agreement [28][29] - The establishment of the joint venture is subject to approval from market supervision authorities, and it is not expected to have a significant impact on the company's 2025 financial performance [38][39]